The G1 phase is the first “gap” in the cell cycle, a stretch of time after a cell finishes dividing and before it begins copying its DNA. During G1, a cell grows in size, ramps up protein production, and evaluates whether conditions are favorable enough to commit to another round of division. It is the cell cycle’s longest and most variable phase, and it contains the single most consequential decision point a cell faces: whether to keep dividing, pause, or stop permanently.
What Actually Happens During G1
The name “gap 1” is a bit misleading. Early cell biologists coined it because G1 seemed like a quiet interval between mitosis (when a cell physically splits in two) and S phase (when DNA gets copied). In reality, G1 is packed with activity. A cell that has just divided is roughly half the size it needs to be, and it spends much of G1 rebuilding. Organelles are duplicated, membranes expand, and the cell synthesizes the enzymes and structural proteins it needs to function. Metabolically, G1 is characterized by a rise in glycolytic activity and a high ratio of certain energy-carrying molecules that favor biosynthesis.1PubMed Central. Cell cycle progression is regulated by intertwined redox oscillators
But the real significance of G1 is not the growth itself. It is the decision-making. Throughout G1, the cell integrates signals from its environment: growth factors delivered by neighboring cells, nutrient availability, attachment to the surrounding tissue, and whether its own DNA is intact. All of these inputs feed into a molecular decision about whether to proceed into S phase or to step aside. That decision is not made all at once. Research indicates that the G1-to-S transition encompasses at least two distinct phases, during which different sets of signaling enzymes are activated in sequence to push the cell forward.2PubMed. Growth factor-dependent signaling and cell cycle progression
The Restriction Point
The most famous feature of G1 is a threshold called the restriction point. First described in 1974, the restriction point is the moment after which a cell no longer needs external growth signals to finish the cycle. Before the restriction point, if you remove growth factors from a cell’s environment, the cell will stop progressing and may slip into a resting state. After the restriction point, the cell is committed: it will barrel through S phase, G2, and mitosis regardless of what happens outside.3PubMed. The restriction point of the cell cycle
You can think of the restriction point as a point of no return. Early in G1, the cell is essentially asking “Should I divide?” and listening carefully to its environment for the answer. Once it crosses the restriction point, the answer is locked in. This is why growth factor signaling early in G1 matters so much. In experiments with cultured cells, withdrawing growth factors immediately after mitosis prevents a key signaling pathway from being activated, and the cells stall out and enter a quiescent state or begin to die.4PubMed Central. Regulation of G1 phase progression by growth factors and the extracellular matrix
How Growth Factors Push a Cell Past the Restriction Point
The molecular machinery behind the restriction point centers on a protein called the retinoblastoma protein, usually abbreviated Rb. In early G1, Rb acts as a brake: it binds to and blocks a family of transcription factors that the cell needs to switch on the genes required for DNA replication. The cell’s job during G1 is to progressively release that brake by modifying Rb through a process called phosphorylation, which essentially means tagging it with phosphate groups until its grip loosens.
This happens in two waves. Early in G1, growth factor signals stimulate the production of a protein called cyclin D, which partners with enzymes called CDK4 and CDK6. These complexes partially phosphorylate Rb, putting it into a state that is modified but still functional enough to hold onto its transcription-factor targets.5PubMed. Hypo-phosphorylation of the retinoblastoma protein (pRb) by cyclin D:Cdk4/6 complexes results in active pRb Then, in late G1, a second wave of enzymes (cyclin E paired with CDK2) piles on additional phosphate groups, fully inactivating Rb and releasing the transcription factors to do their work.6PubMed Central. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo Once those genes switch on, the cell has the tools it needs to enter S phase and begin copying its chromosomes.
This two-wave system creates a built-in delay that gives the cell time to verify conditions before committing. The first wave depends heavily on external growth factors. The second wave is partly self-reinforcing: once a small amount of cyclin E is made, it activates more of the genes that produce cyclin E, creating a feedback loop that drives the cell forward with increasing momentum. That self-reinforcing loop is essentially what makes the restriction point irreversible.
Preparing DNA for Replication
While the restriction-point machinery decides whether the cell will divide, G1 also hosts another critical process: origin licensing. Before DNA can be copied in S phase, the cell must mark the specific locations along each chromosome where replication will begin. It does this by loading protein complexes called MCM (minichromosome maintenance) helicases onto the DNA at these sites, a step known as origin licensing.7eLife. Rapid DNA replication origin licensing protects stem cell pluripotency
Origin licensing can only happen during G1, and for good reason. The enzymes that drive DNA replication in S phase are the same ones that block new origins from being licensed. This separation ensures each stretch of DNA gets copied exactly once per cycle. If a cell rushes into S phase before enough origins are licensed, it risks incomplete replication and genomic instability. Studies in yeast have shown that a protein called Sic1 helps protect this timing by keeping S-phase enzymes from activating prematurely, giving the cell enough time in late G1 to finish licensing.8PubMed. The yeast CDK inhibitor Sic1 prevents genomic instability by promoting replication origin licensing in late G(1)
The G1 DNA Damage Checkpoint
If a cell’s DNA has been damaged, entering S phase would be dangerous. Copying a damaged template could permanently lock in mutations or cause chromosomes to break. Cells have a safety mechanism for this: the G1 DNA damage checkpoint. When DNA damage is detected, a signaling cascade activates a protein called p53, which in turn ramps up production of p21. This protein jams the cyclin-CDK complexes that drive the cell through late G1, effectively slamming the brakes on the entire process.
The sensor at the top of this cascade is a kinase called ATM, which detects double-strand DNA breaks. Research in mice has shown that blocking ATM activity prevents p21 from being properly switched on, which eliminates the G1 arrest response after radiation exposure and forces damaged cells into S phase prematurely.9PubMed Central. Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiation This is more than an academic detail: the G1 damage checkpoint is one of the body’s most important defenses against cancer. When the genes encoding p53 or its downstream targets are mutated, cells lose the ability to pause in G1 after DNA damage, and they accumulate mutations at a much faster rate.
Stepping Out of the Cycle Entirely
Not every cell that enters G1 continues dividing. Many cells exit the cycle and enter a resting state called G0. Neurons in the adult brain, fully mature muscle fibers, and many specialized cell types park in G0 for months, years, or the rest of your life. These cells are alive and metabolically active, but they have stopped progressing through the cell cycle.
The transition between G0 and active cycling is not instantaneous. When resting human T cells (a type of immune cell) are stimulated to begin dividing, they pass through a commitment point roughly three to five hours after stimulation. Before that commitment point, the cells can still fall back into G0. Crossing it requires the activity of the same cyclin D and CDK4/6 complexes that drive early G1 in already-cycling cells. Blocking those complexes during the first few hours of stimulation keeps T cells locked in G0.10PubMed Central. Commitment point during G0–>G1 that controls entry into the cell cycle
The machinery for re-entering the cycle from G0 has been well studied, but researchers have noted that most of what we understand about growth factor signaling and cycle progression comes from work on G1 itself. The role of growth factors in later phases remains much less clear.11PubMed Central. Regulation of Cell Cycle Progression by Growth Factor-Induced Cell Signaling
When G1 Arrest Becomes Permanent
Quiescence in G0 is typically reversible: give a resting cell the right signals, and it can re-enter G1 and divide again. Senescence is different. Senescent cells are stuck in a state that resembles late G1 arrest but is functionally permanent. They cannot be coaxed back into dividing.
Work on aging human fibroblasts has shown that senescent cells arrest specifically in late G1, not in G0. Their chromatin (the packaged form of DNA) shows a condensation pattern consistent with late G1, and they are excluded from the reversible G0 resting state that younger cells enter when they stop growing.12PubMed. The pathway of cell senescence: WI-38 cells arrest in late G1 and are unable to traverse the cell cycle from a true G0 state One way to tell quiescent and senescent cells apart is by looking at protein synthesis: senescent cells continue actively making proteins, whereas truly quiescent cells dial protein production way down.13PubMed Central. Different Stages of Quiescence, Senescence, and Cell Stress Identified by Molecular Algorithm Based on the Expression of Ki67, RPS6, and Beta-Galactosidase Activity
This distinction matters for aging and disease. Senescent cells accumulate in tissues as you age, and because they are metabolically active, they secrete inflammatory signals that can affect their neighbors. The fact that they are stuck in a G1-like state rather than truly at rest helps explain why they are so different from harmless quiescent cells, and why clearing them from tissues is an active area of anti-aging research.
Why G1 Length Varies So Much Between Cell Types
G1 is the most variable phase of the cell cycle. In a typical human cell dividing every 24 hours, G1 might last around 10 to 12 hours. But in embryonic stem cells, G1 is dramatically compressed. These cells cycle extremely rapidly and have a truncated G1 phase, spending proportionally more of their cycle time in S phase instead.14PubMed Central. G1 to S phase cell cycle transition in somatic and embryonic stem cells
For a long time, researchers assumed that this short G1 was essential for keeping stem cells in their undifferentiated, pluripotent state. The logic seemed straightforward: a longer G1 would give the cell more time to respond to differentiation signals, pushing it toward becoming a specialized cell type. And when stem cells do begin to differentiate, G1 does lengthen.15PubMed Central. Linking the Cell Cycle to Cell Fate Decisions But the relationship turns out to be less rigid than expected. Studies in mouse embryonic stem cells have shown that artificially lengthening G1 does not necessarily force differentiation. Those cells can maintain their pluripotent state even with an elongated G1.16PubMed Central. Gap 1 phase length and mouse embryonic stem cell self-renewal So G1 length correlates with differentiation but does not single-handedly cause it.
At the other extreme, some adult cells have G1 phases lasting days or weeks, particularly in tissues that divide rarely under normal conditions, like the liver. And some cells, as discussed above, exit G1 into G0 and stay there indefinitely. The flexibility of G1 is what makes it the cell cycle’s main throttle: by stretching or compressing this one phase, the body controls how fast different tissues grow and renew.
Cell Size and G1
One of the quieter jobs of G1 is making sure the cell is physically large enough before it enters S phase. A cell that copies its DNA and divides before growing sufficiently would produce progressively smaller daughter cells, which is not sustainable. How does a cell know it is big enough? One hypothesis is that the cell monitors its own rate of protein translation. As a cell grows, it accumulates more ribosomes, and total translational output rises. Certain proteins produced by this translation machinery act as “sizers,” accumulating until they hit a threshold that triggers progression past a G1 control point.17PubMed Central. Cell Cycle Regulation by Checkpoints
In yeast, researchers have shown that manipulating intracellular signaling can change the critical size threshold directly. Raising levels of cAMP, a signaling molecule, increases the minimum cell size a yeast cell must reach before it can pass through the G1-to-S transition.18PubMed. cAMP-mediated increase in the critical cell size required for the G1 to S transition in Saccharomyces cerevisiae This ties cell size control to nutrient sensing: the same pathways that regulate ribosome production in response to available nutrients also influence how big a cell needs to get before it can divide. When nutrients are scarce, translational activity drops, the effective size threshold rises, and G1 lengthens.
Metabolism Shifts During G1
G1 is not just structurally and genetically busy. Its metabolic profile is distinct from other phases. Cells in G1 show elevated glycolytic activity, meaning they break down glucose at a high rate to generate the building blocks needed for growth. This is accompanied by a transient dip in intracellular pH, likely from lactic acid production, followed by a shift back toward alkaline conditions as the cell prepares for S phase. The cell membrane becomes hyperpolarized (more negatively charged on the inside), driven by sodium-potassium pump activity.1PubMed Central. Cell cycle progression is regulated by intertwined redox oscillators
In cancer cells, these metabolic features become exaggerated and tangled up with the cell cycle machinery in unusual ways. Certain metabolic enzymes that normally stay in the cytoplasm periodically move into the nucleus during G1 and directly regulate cell cycle genes. One well-studied example is an enzyme involved in glucose metabolism that, in cancer cells, moonlights as a transcriptional regulator during G1, helping to promote the expression of genes that drive proliferation.19PubMed. Interconnection between Metabolism and Cell Cycle in Cancer This blurring of the boundary between metabolism and cell cycle control is one reason cancer cells are so difficult to rein in: the usual checkpoints and regulatory logic get rewired.
G1 Machinery as a Cancer Drug Target
Because so many cancers rely on overactive G1 progression to sustain their rapid growth, the molecular machinery of G1 has become a prime drug target. The most prominent example is the development of CDK4/6 inhibitors, drugs that block the same cyclin D-CDK4/6 complexes responsible for the first wave of Rb phosphorylation in early G1. By jamming these complexes, the drugs prevent Rb from being inactivated and keep cells from progressing past the restriction point.
Three CDK4/6 inhibitors (palbociclib, ribociclib, and abemaciclib) are now used in clinical oncology, most prominently for certain types of breast cancer. Their primary mechanism is inducing G1 arrest in cancer cells, but researchers have found that they also alter cancer cell biology in other ways that contribute to their effectiveness, including effects on metabolism, immune signaling, and DNA repair.20PubMed Central. CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest These drugs work best in cancers that still have a functional Rb protein, since the whole point is to keep Rb in its active, brake-applying state. In tumors where Rb is already lost or mutated, blocking CDK4/6 has nothing left to protect, and the drugs are largely ineffective.
The success of CDK4/6 inhibitors has renewed interest in other G1 regulators as potential targets. Cyclin E overexpression, for example, is a common feature of aggressive ovarian and breast cancers and can drive cells past the restriction point even when early G1 signals are suppressed. Whether targeting cyclin E-CDK2 directly will prove as therapeutically useful remains an open and active question in cancer biology.